Production of 149Tb, 152Tb, 155Tb and 161Tb from gadolinium using different light-particle beams

Rahman, A. K. M. Rezaur; Awal, Abdul

doi:10.1007/s10967-019-06973-0

Cited by 20 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three main production routes have been reported: (i) via the 152 Gd(p,4n) 149 Tb reaction [ 267 , 268 , 269 ]. This light particle induced reaction on 152 Gd requires a proton energy beam of around 50 MeV and can be performed in commercial high energy cyclotrons (70 MeV).…”

Section: Terbium-149mentioning

confidence: 99%

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

et al. 2021

View full text Add to dashboard Cite

Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium-149 and thorium-227 are considered as the most suitable. Despite common general features, they all have their own physical characteristics that make them singular and so promising for TAT. These radionuclides were largely studied over the last two decades, leading to a better knowledge of their production process and chemical behavior, allowing for an increasing number of biological evaluations. The aim of this review is to summarize the main properties of these eight chosen radionuclides. An overview from their availability to the resulting clinical studies, by way of chemical design and preclinical studies is discussed.

show abstract

Section: Terbium-149mentioning

confidence: 99%

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To date, the availability of these radionuclides has limited their translation into clinical routine. [260] Terbium-149, 152 Tb, and 155 Tb were so far produced and isolated by the isotope and separation online facility (ISOLDE) at European Council for Nuclear Research (CERN) via a highenergy (1.4 GeV) proton-induced spallation of tantalum foil targets. [255a] To separate the desired radioisotopes and their isobars and pseudoisobars, a mass separator is required.…”

Section: Production and Availabilitymentioning

confidence: 99%

Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer

et al. 2021

View full text Add to dashboard Cite

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic applications. The imaging modalities positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are based on γ-emissions of specific energies. The therapeutic technologies are based on β À -particle-, α-particle-, and Auger electron emitters. In oncology, PET and SPECT are used to detect cancer lesions, to determine dosimetry, and to monitor therapy effectiveness. In contrast, radiotherapy is designed to irreparably damage tumor cells in order to eradicate or control the disease's progression. Radiometals are being explored for the development of diagnostic and therapeutic radiopharmaceuticals. Strategies that combine both modalities (diagnostic and therapeutic), referred to as theranostics, are promising candidates for clinical applications. This review provides an overview of the basic concepts behind therapeutic and diagnostic radiopharmaceuticals and their significance in contemporary oncology. Select radiometals that significantly impact current and upcoming cancer treatment strategies are grouped as clinically suitable theranostics pairs. The most important physical and chemical properties are discussed. Standard production methods and current radionuclide availability are provided to indicate whether a cost-efficient use in a clinical routine is feasible. Recent preclinical and clinical developments and outline perspectives for the radiometals are highlighted in each section.

show abstract

“…Accurate nuclear cross section data that need to be provided to predict the tritium breeding capability, assess the shielding efficiency, estimate the nuclear power generated in the system, and produce activation and radiation damaged data for the irradiated materials/components (Fischer et al 2018). The new evaluated nuclear data plays an efficient role in nuclear technology (Rahman & Awal 2020;Rahman et al 2019;Lorenz & Schmidt, 1986). Evaluation of nuclear data is a continuous process and the evaluation of cross-section data is very important for those who have experimental difficulty and are hopeless for measuring the cross-section data (Rahman& Zubair 2020a; Rahman 2012a).…”

Section: Introductionmentioning

confidence: 99%

NEUTRON INDUCED 55Mn REACTION IN THE ENERGY RANGE 0.001 MeV TO 40 MeV

Rahman,

Happy,

Ovi

et al. 2023

MJS

View full text Add to dashboard Cite

Neutron induced 55Mn reactions are evaluated in the energy range 0.001 MeV to 40 MeV using TALYS 1.95 computer code. During this evaluation, local and global parameterisations of Koning and Delaroche are used in nuclear optical model. Comparisons were made with experimental data, collected from EXFOR and other sources. Some optical model parameters (OMP) were needed to be adjusted for better agreement between theoretical calculations and experimental findings. Various evaluated libraries such as ENDF, JENDL etc. are being checked and compared with our evaluation. TALYS evaluation shows better agreement when parameters were adjusted.

show abstract

Production of 149Tb, 152Tb, 155Tb and 161Tb from gadolinium using different light-particle beams

Cited by 20 publications

References 16 publications

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”

Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer

NEUTRON INDUCED 55Mn REACTION IN THE ENERGY RANGE 0.001 MeV TO 40 MeV

Contact Info

Product

Resources

About